

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED**

**精優藥業控股有限公司\***

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 00858)**

**POLL RESULTS OF THE SPECIAL GENERAL MEETING  
HELD ON 30 JULY 2021**

Reference is made to the circular dated 14 July 2021 (the “**Circular**”) issued by the Company and the notice of SGM (the “**Notice**”) attached hereto. Capitalized terms used herein shall have the same meanings as those defined in the Circular unless the context requires otherwise.

The SGM was held on 30 July 2021 to consider the ordinary resolution as set out in the Notice regarding the Second Amendments.

As at the date of the SGM, the total number of Shares in issue was 2,390,000,000. As stated in the Circular, Dr. Mao Yumin holding approximately 7.94% (189,920,000 Shares) of the Shares in issue, shall be required to abstain from voting on the proposed ordinary resolution at the SGM. Accordingly, the total number of Shares entitling the Shareholders to attend and vote for or against on the resolution at the SGM was 2,200,080,000 Shares, representing approximately 92.06% of the total number of Shares in issue as at the time of the SGM. There was no Shareholder who was entitled to attend and vote only against the resolution at the SGM.

The Company is pleased to announce the poll results in respect of the resolution proposed at the SGM as follow:

ORDINARY RESOLUTION		Number of Votes (%) (Note)	
		For	Against
1.	To approve, ratify and confirm the second amendment deed and the second deed of waiver both dated 12 May 2021 entered into between the Company and Innovative Pharmaceutical Biotech Limited (“ <b>Innovative</b> ”) in relation to the amendment of certain terms and conditions (the “ <b>Second Amendments</b> ”) of the convertible bonds issued by Innovative to the Company in the principal amount of HK\$715,000,000 and all transactions contemplated thereunder including the Second Amendments and authorize the directors of the Company to do all such acts and things (including, without limitation, signing, executing (under hand or under seal)) to give effect to the Second Amendments.	360,630,690 (98.01%)	7,320,000 (1.99%)

*Note:* The number of votes and percentage of the voting are based on the total number of Shares held by the Shareholders who voted at the SGM in person, by authorized corporate representative(s) or by proxies.

As more than 50% of the votes were cast in favour of the above resolution, the proposed resolution was duly passed as an ordinary resolution of the Company.

The branch share registrar and transfer office of the Company in Hong Kong, Tricor Tengis Limited, acted as scrutineer for the vote-taking at the SGM.

By order of the Board  
**Extrawell Pharmaceutical Holdings Limited**  
**Xie Yi**  
*Chairman*

Hong Kong, 30 July 2021

*As at the date of this announcement, the executive Directors are Dr. Xie Yi, Mr. Cheng Yong, Dr. Lou Yi, Ms. Wong Sau Kuen and Mr. Liu Kwok Wah, and the independent non-executive Directors are Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.*

\* For identification purpose only